A retrospective single institutional analysis of outpatient chemotherapy in patients with cancer during the COVID-19 pandemic.

Autor: Shimanuki Y; Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan., Shimomura A; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Ogawa C; Department of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan., Komuro M; Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan., Terakado H; Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan., Nishimura T; Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan., Shimizu C; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.

Publikováno v: Global health & medicine [Glob Health Med] 2024 Aug 31; Vol. 6 (4), pp. 268-272.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Exploratory study on relative dose intensity and reasons for dose reduction of adjuvant CAPOX therapy in elderly patients with colorectal cancer.

Autor: Tsuchiya A; Pharmaceutical Department, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan., Ogawa C; Pharmaceutical Department, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan., Kondo N; Pharmaceutical Department, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan., Kojima Y; Gastroenterology, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan., Yamada Y; Comprehensive Cancer Center, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan., Terakado H; Pharmaceutical Department, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.

Publikováno v: Global health & medicine [Glob Health Med] 2022 Jun 30; Vol. 4 (3), pp. 180-185.

Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?

Autor: Tanaka M; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Shimomura A; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Terakado H; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Shimizu C; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Nov 10; Vol. 39 (32), pp. 3647-3648. Date of Electronic Publication: 2021 Sep 10.

Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?

Autor: Shimanuki Y; Yumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Shimomura A; Yumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Yoshimura K; Yumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Terakado H; Yumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Shimizu C; Yumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Nov 01; Vol. 39 (31), pp. 3521-3522. Date of Electronic Publication: 2021 Sep 23.